All Stories

  1. Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma

    Article • Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, January 2023, Tsinghua University Press

    Dr ALESSANDRO Gozzetti

  2. Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

    Article • Frontiers in Oncology, December 2020, Frontiers

    Dr ALESSANDRO Gozzetti

  3. A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin

    Article • Turkish Journal of Hematology, November 2020, Journal of Clinical Research of Pediatric Endocrinology

    Dr ALESSANDRO Gozzetti

  4. Daratumumab efficacy in extramedullary orbital myeloma

    Article • Clinical Case Reports, October 2020, Wiley

    Dr ALESSANDRO Gozzetti

  5. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Article • Blood Cancer Journal, October 2020, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  6. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

    Article • Journal of Personalized Medicine, September 2020, MDPI AG

    Dr ALESSANDRO Gozzetti

  7. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

    Article • Leukemia, September 2020, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  8. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

    Article • Blood, August 2020, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  9. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

    Article • Frontiers in Medicine, August 2020, Frontiers

    Dr ALESSANDRO Gozzetti

  10. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

    Article • Clinical Case Reports, July 2020, Wiley

    Dr ALESSANDRO Gozzetti

  11. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Article • Leukemia & Lymphoma, April 2020, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  12. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    Article • American Journal of Hematology, February 2020, Wiley

    Dr ALESSANDRO Gozzetti

  13. Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region

    Article • Farmeconomia Health economics and therapeutic pathways, February 2020, Seed SRL

    Dr ALESSANDRO Gozzetti

  14. High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

    Article • Haematologica, January 2020, Ferrata Storti Foundation (Haematologica)

    Dr ALESSANDRO Gozzetti

  15. Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?

    Article • Clinical Hematology International, January 2020, Atlantis Press

    Dr ALESSANDRO Gozzetti

  16. LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2019, Elsevier

    Dr ALESSANDRO Gozzetti

  17. Hematogenous extramedullary relapse in multiple myeloma ‐ a multicenter retrospective study in 127 patients

    Article • American Journal of Hematology, August 2019, Wiley

    Dr ALESSANDRO Gozzetti

  18. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12

    Article • Cancers, June 2019, MDPI AG

    Dr ALESSANDRO Gozzetti

  19. Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia

    Article • Cytometry Part B Clinical Cytometry, February 2019, Wiley

    Dr ALESSANDRO Gozzetti

  20. Evidences of new risk factors for retinal vein thrombosis

    Article • Acta Ophthalmologica, December 2018, Wiley

    Dr ALESSANDRO Gozzetti

  21. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2018, Elsevier

    Dr ALESSANDRO Gozzetti

  22. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients

    Article • Leukemia & Lymphoma, July 2018, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  23. Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

    Article • Frontiers in Oncology, May 2018, Frontiers

    Dr ALESSANDRO Gozzetti

  24. Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia

    Article • British Journal of Haematology, February 2018, Wiley

    Dr ALESSANDRO Gozzetti

  25. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

    Article • British Journal of Haematology, January 2018, Wiley

    Dr ALESSANDRO Gozzetti

  26. Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal

    Article • American Journal of Clinical Pathology, November 2017, Oxford University Press (OUP)

    Dr ALESSANDRO Gozzetti

  27. Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis

    Article • Neurological Sciences, October 2017, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  28. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia

    Article • Blood, September 2017, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  29. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study

    Article • Annals of Hematology, August 2017, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  30. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

    Article • Anti-Cancer Agents in Medicinal Chemistry, July 2017, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  31. FLT3 Inhibitors in the Management of Acute Myeloid Leukemia

    Article • Anti-Cancer Agents in Medicinal Chemistry, July 2017, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  32. Second Generation Proteasome Inhibitors in Multiple Myeloma

    Article • Anti-Cancer Agents in Medicinal Chemistry, June 2017, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  33. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies

    Article • Anti-Cancer Agents in Medicinal Chemistry, June 2017, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  34. IgM myeloma: A multicenter retrospective study of 134 patients

    Article • American Journal of Hematology, May 2017, Wiley

    Dr ALESSANDRO Gozzetti

  35. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma

    Article • American Journal of Hematology, April 2017, Wiley

    Dr ALESSANDRO Gozzetti

  36. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

    Article • Blood, November 2016, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  37. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study

    Article • British Journal of Haematology, September 2016, Wiley

    Dr ALESSANDRO Gozzetti

  38. Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release

    Article • Cell Reports, June 2016, Elsevier

    Dr ALESSANDRO Gozzetti

  39. Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials

    Article • Reviews on Recent Clinical Trials, May 2016, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  40. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

    Article • American Journal of Hematology, April 2016, Wiley

    Dr ALESSANDRO Gozzetti

  41. Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release

    Article • Cell Reports, April 2016, Elsevier

    Dr ALESSANDRO Gozzetti

  42. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?

    Article • British Journal of Haematology, March 2016, Wiley

    Dr ALESSANDRO Gozzetti

  43. Central nervous system multiple myeloma

    Article • Annals of Hematology, January 2016, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  44. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

    Article • Leukemia & Lymphoma, January 2016, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  45. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Article • The Lancet Oncology, January 2016, Elsevier

    Dr ALESSANDRO Gozzetti, Dr Albert Oriol

  46. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

    Article • Leukemia Research, October 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  47. Intravenous Bortezomib (IV) infusion after Non Response to Subcutaneous Bortezomib (SQ) administration can induce transitory responses in multiple myeloma patients: is some patient more sensitive to the IV bortezomib?

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  48. Bortezomib based therapies and High Cut Off filter dyalysis (HCO) are effective in Multiple Myeloma patients with end stage renal failure

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  49. Skin Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 53 Patients

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  50. Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  51. Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients

    Article • Oncotarget, July 2015, Impact Journals, LLC

    Dr ALESSANDRO Gozzetti

  52. Central Nervous System Multiple Myeloma

    Article • Clinical Lymphoma Myeloma & Leukemia, June 2015, Elsevier

    Dr ALESSANDRO Gozzetti

  53. Evolving Treatments in Multiple Myeloma Patients with Renal Failure

    Article • Reviews on Recent Clinical Trials, March 2015, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  54. Novel Agents in CNS Myeloma Treatment

    Article • Central Nervous System Agents in Medicinal Chemistry, November 2014, Bentham Science Publishers

    Dr ALESSANDRO Gozzetti

  55. Central Nervous System Myeloma and New Drugs: Can we Begin the Fight?

    Article • Global Journal of Hematology and Blood Transfusion, November 2014, Cosmos Scholars Publishing House

    Dr ALESSANDRO Gozzetti

  56. Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders

    Article • Leukemia & Lymphoma, November 2014, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  57. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study

    Article • American Journal of Hematology, September 2014, Wiley

    Dr ALESSANDRO Gozzetti

  58. Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection

    Article • Haematologica, September 2014, Ferrata Storti Foundation (Haematologica)

    Dr ALESSANDRO Gozzetti

  59. Therapeutic Advancements in Multiple Myeloma

    Article • Frontiers in Oncology, September 2014, Frontiers

    Dr ALESSANDRO Gozzetti

  60. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia

    Article • Leukemia Research, August 2014, Elsevier

    Dr ALESSANDRO Gozzetti

  61. Central nervous system multiple myeloma: a different cytogenetic profile

    Article • British Journal of Haematology, February 2014, Wiley

    Dr ALESSANDRO Gozzetti

  62. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas

    Article • Leukemia & Lymphoma, January 2014, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  63. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

    Article • Blood Cancer Journal, November 2013, Nature

    Dr ALESSANDRO Gozzetti

  64. Treatment of smoldering multiple myeloma

    Article • Nature Reviews Clinical Oncology, November 2013, Nature

    Dr ALESSANDRO Gozzetti

  65. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia

    Article • Cancer, October 2013, Wiley

    Dr ALESSANDRO Gozzetti

  66. Commentary

    Article • Journal of Neurosciences in Rural Practice, October 2013, Thieme Publishing Group

    Dr ALESSANDRO Gozzetti

  67. Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation

    Article • Annals of Hematology, May 2013, Springer Science + Business Media

    Professor Daniel Remondini, Professor Enrico Tagliafico, Dr ALESSANDRO Gozzetti

  68. Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up

    Article • Hematological Oncology, November 2012, Wiley

    Dr ALESSANDRO Gozzetti

  69. Lenalidomide maintenance in myeloma

    Article • Nature Reviews Clinical Oncology, September 2012, Nature

    Dr ALESSANDRO Gozzetti

  70. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

    Article • Blood, July 2012, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  71. Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

    Article • Mediterranean Journal of Hematology and Infectious Diseases, June 2012, Institute of Hematology, Catholic University

    Dr ALESSANDRO Gozzetti

  72. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

    Article • Blood, June 2012, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  73. Evaluation of residual CD34+Ph+progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

    Article • Cancer, April 2012, Wiley

    Dr ALESSANDRO Gozzetti

  74. Extramedullary myeloma relapses

    Article • Annals of Hematology, February 2012, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  75. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

    Article • British Journal of Haematology, February 2012, Wiley

    Dr ALESSANDRO Gozzetti

  76. Extramedullary multifocal plasmacytoma relapse in multiple myeloma

    Article • Leukemia Research, January 2012, Elsevier

    Dr ALESSANDRO Gozzetti

  77. Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients

    Article • Leukemia Research and Treatment, January 2012, Hindawi Publishing Corporation

    Dr ALESSANDRO Gozzetti

  78. EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma

    Article • Advances in Hematology, January 2012, Hindawi Publishing Corporation

    Dr ALESSANDRO Gozzetti

  79. Plasmacytoma of the skull

    Article • European Journal Of Haematology, November 2011, Wiley

    Dr ALESSANDRO Gozzetti

  80. A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report

    Article • Leukemia Research, November 2011, Elsevier

    Dr ALESSANDRO Gozzetti

  81. Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy

    Article • Skeletal Radiology, September 2011, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  82. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients

    Article • Cancer, August 2011, Wiley

    Dr ALESSANDRO Gozzetti

  83. Unusual localizations of plasmacytoma

    Article • Leukemia Research, July 2011, Elsevier

    Dr ALESSANDRO Gozzetti

  84. 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

    Article • Genes Chromosomes and Cancer, May 2011, Wiley

    Dr Francesco Bertoni, Dr ALESSANDRO Gozzetti

  85. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

    Article • Cancer, February 2011, Wiley

    Dr ALESSANDRO Gozzetti

  86. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients

    Article • Annals of Oncology, January 2011, Oxford University Press (OUP)

    Dr ALESSANDRO Gozzetti

  87. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phas...

    Article • The Lancet, December 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  88. Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma

    Article • Leukemia Research, November 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  89. Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  90. Hyperlipidemia in a myeloma patient after bortezomib treatment

    Article • Leukemia Research, September 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  91. Lenalidomide efficacy in bortezomib-resistant myeloma

    Article • Nature Reviews Clinical Oncology, September 2010, Nature

    Dr ALESSANDRO Gozzetti

  92. Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination

    Article • Nature Reviews Clinical Oncology, August 2010, Nature

    Dr ALESSANDRO Gozzetti

  93. Predicting the clinical course of Hodgkin lymphoma

    Article • Nature Reviews Clinical Oncology, August 2010, Nature

    Dr ALESSANDRO Gozzetti

  94. Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib

    Article • Leukemia Research, August 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  95. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

    Article • Cancer Genetics and Cytogenetics, June 2010, Elsevier

    Dr Carmen Baldazzi, Dr ALESSANDRO Gozzetti

  96. Physicians and end-of-life issues

    Article • Cancer, May 2010, Wiley

    Dr ALESSANDRO Gozzetti

  97. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin

    Article • European Journal Of Haematology, May 2010, Wiley

    Dr ALESSANDRO Gozzetti, Michela Cini

  98. Hyperlipidemic myeloma

    Article • Annals of Hematology, February 2010, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  99. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion

    Article • British Journal of Haematology, February 2010, Wiley

    Dr ALESSANDRO Gozzetti

  100. Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  101. Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia

    Article • Cancer Genetics and Cytogenetics, February 2010, Elsevier

    Dr ALESSANDRO Gozzetti

  102. A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2

    Article • Acta Haematologica, January 2010, Karger Publishers

    Dr ALESSANDRO Gozzetti

  103. BCR-ABL DERIVED PEPTIDE VACCINES FOR CHRONIC MYELOID LEUKAEMIA

    Article • Journal of the Siena Academy of Sciences, November 2009, PAGEPress Publications

    Dr ALESSANDRO Gozzetti

  104. PATHOGENETIC ASPECTS OF MYELODISPLASTIC SYNDROMES

    Article • Journal of the Siena Academy of Sciences, November 2009, PAGEPress Publications

    Dr ALESSANDRO Gozzetti

  105. PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT

    Article • Journal of the Siena Academy of Sciences, November 2009, PAGEPress Publications

    Dr ALESSANDRO Gozzetti

  106. Bortezomib and restoration of chemosensitivity

    Article • Nature Reviews Clinical Oncology, November 2009, Nature

    Dr ALESSANDRO Gozzetti

  107. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

    Article • Blood, October 2009, American Society of Hematology

    Dr ALESSANDRO Gozzetti

  108. Cutaneous myeloma and bortezomib

    Article • Annals of Hematology, July 2009, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  109. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors

    Article • British Journal of Haematology, July 2009, Wiley

    Dr Francesco Bertoni, Dr ALESSANDRO Gozzetti, Valeria Maria Pinto

  110. Isolated deletion of 6q in a patient with myelodysplastic syndrome

    Article • Cancer Genetics and Cytogenetics, July 2009, Elsevier

    Dr ALESSANDRO Gozzetti

  111. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia

    Article • European Journal Of Haematology, April 2009, Wiley

    Dr ALESSANDRO Gozzetti

  112. Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

    Article • Clinical Lymphoma & Myeloma, April 2009, Elsevier

    Dr ALESSANDRO Gozzetti

  113. B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results

    Article • Clinical Lymphoma & Myeloma, February 2009, Elsevier

    Dr ALESSANDRO Gozzetti

  114. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

    Article • Hematological Oncology, December 2008, Wiley

    Dr ALESSANDRO Gozzetti

  115. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis

    Article • British Journal of Haematology, June 2008, Wiley

    Dr ALESSANDRO Gozzetti

  116. Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay

    Article • Neuroradiology, May 2008, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  117. The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients

    Article • Calcified Tissue International, April 2008, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  118. Unusual Discordant Responses in Two Multiple Myeloma Patients during Bortezomib Treatment

    Article • Onkologie, January 2008, Karger Publishers

    Dr ALESSANDRO Gozzetti

  119. Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogenetics

    Article • Cancer Genetics and Cytogenetics, January 2008, Elsevier

    Dr ALESSANDRO Gozzetti

  120. Reply to ‘Rituximab activity in CD20-positive multiple myeloma’

    Article • Leukemia, November 2007, Nature

    Dr ALESSANDRO Gozzetti

  121. Insights into JAK2-V617F mutation in CML

    Article • The Lancet Oncology, October 2007, Elsevier

    Dr ALESSANDRO Gozzetti

  122. Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma

    Article • British Journal of Haematology, October 2007, Wiley

    Dr ALESSANDRO Gozzetti

  123. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

    Article • Leukemia, August 2007, Nature

    Dr ALESSANDRO Gozzetti

  124. Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia

    Article • Cancer Genetics and Cytogenetics, August 2007, Elsevier

    Dr ALESSANDRO Gozzetti

  125. Characterization of Ph-negative abnormal clones emerging during imatinib therapy

    Article • Cancer, June 2007, Wiley

    Dr ALESSANDRO Gozzetti

  126. Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study

    Article • Journal of Clinical Oncology, June 2007, American Society of Clinical Oncology (ASCO)

    Dr ALESSANDRO Gozzetti

  127. Reply to Rituximab activity in CD20 positive multiple myeloma

    Article • Leukemia, June 2007, Nature

    Dr ALESSANDRO Gozzetti

  128. Trisomy 8 in chronic lymphocytic leukemia: a report of two cases

    Article • Cancer Genetics and Cytogenetics, June 2007, Elsevier

    Dr ALESSANDRO Gozzetti

  129. Deletion 9q in a patient with concomitant myelodysplasia and non-Hodgkin lymphoma

    Article • Cancer Genetics and Cytogenetics, June 2007, Elsevier

    Dr ALESSANDRO Gozzetti

  130. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia

    Article • Haematologica, April 2007, Ferrata Storti Foundation (Haematologica)

    Dr ALESSANDRO Gozzetti

  131. Multiple Myeloma Involving the Cavernous Sinus: A Report of 3 Cases and Response to Bortezomib

    Article • Clinical Lymphoma & Myeloma, March 2007, Elsevier

    Dr ALESSANDRO Gozzetti

  132. Promyelocytic Blast Crisis of Chronic Myelogenous Leukemia during Imatinib Treatment

    Article • Acta Haematologica, January 2007, Karger Publishers

    Dr ALESSANDRO Gozzetti

  133. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype

    Article • Hematological Oncology, January 2007, Wiley

    Dr ALESSANDRO Gozzetti

  134. Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

    Article • Acta Haematologica, January 2007, Karger Publishers

    Dr ALESSANDRO Gozzetti

  135. Trisomy 22 as sole cytogenetic abnormality in acute monoblastic leukemia (M5b)

    Article • Cancer Genetics and Cytogenetics, August 2006, Elsevier

    Dr ALESSANDRO Gozzetti

  136. Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: A metabolic adaptation?

    Article • Hematology, August 2006, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  137. Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission

    Article • Cancer Genetics and Cytogenetics, June 2006, Elsevier

    Dr ALESSANDRO Gozzetti

  138. Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia

    Article • Clinical Lymphoma & Myeloma, May 2006, Elsevier

    Dr ALESSANDRO Gozzetti

  139. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia

    Article • Leukemia, November 2005, Nature

    Dr ALESSANDRO Gozzetti

  140. Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia

    Article • Hematology, October 2005, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  141. Massive intravascular hemolysis: a fatal complication ofClostridium perfringenssepticemia in a patient with acute lymphoblastic leukemia

    Article • Leukemia & Lymphoma, May 2005, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  142. Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma

    Article • The Oncologist, April 2005, Alphamed Press

    Dr ALESSANDRO Gozzetti

  143. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

    Article • The Lancet, February 2005, Elsevier

    Dr ALESSANDRO Gozzetti

  144. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

    Article • The Lancet, February 2005, Elsevier

    Dr ALESSANDRO Gozzetti

  145. Trisomy 13 in a patient with idiopathic myelofibrosis

    Article • Cancer Genetics and Cytogenetics, January 2005, Elsevier

    Dr ALESSANDRO Gozzetti

  146. Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis

    Article • Leukemia & Lymphoma, January 2005, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  147. Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease

    Article • Hematology, October 2004, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  148. A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia

    Article • Cancer Genetics and Cytogenetics, October 2004, Elsevier

    Dr ALESSANDRO Gozzetti

  149. Effect of 5637 conditioned medium (CM) on the mitotic index in the cytogenetic evaluation of myeloproliferative disorders

    Article • Annales de Génétique, October 2004, Elsevier

    Dr ALESSANDRO Gozzetti

  150. Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia

    Article • Hematology, October 2004, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  151. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements

    Article • Genes Chromosomes and Cancer, April 2004, Wiley

    Dr ALESSANDRO Gozzetti

  152. A case of adult acute myelocytic leukemia (M5a) with a near-tetraploid karyotype characterized by monosomies 5 and 16

    Article • Cancer Genetics and Cytogenetics, April 2004, Elsevier

    Dr ALESSANDRO Gozzetti

  153. A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase

    Article • Cancer Genetics and Cytogenetics, April 2004, Elsevier

    Dr ALESSANDRO Gozzetti

  154. The Use of FluorescenceIn SituHybridization (FISH) in Chronic Lymphocytic Leukemia (CLL)

    Article • Hematology, February 2004, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  155. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

    Article • The Hematology Journal, January 2004, Nature

    Dr ALESSANDRO Gozzetti

  156. A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate

    Article • Cancer Genetics and Cytogenetics, January 2004, Elsevier

    Dr ALESSANDRO Gozzetti

  157. An unusual presentation of chronic B-cell lymphocytic leukaemia

    Article • British Journal of Haematology, December 2003, Wiley

    Dr ALESSANDRO Gozzetti

  158. Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues

    Article • Histopathology, November 2003, Wiley

    Dr ALESSANDRO Gozzetti

  159. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI)

    Article • European Journal Of Haematology, September 2003, Wiley

    Dr ALESSANDRO Gozzetti

  160. A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement

    Article • Cancer Genetics and Cytogenetics, July 2003, Elsevier

    Dr ALESSANDRO Gozzetti

  161. Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin’s lymphoma by interphase fluorescence in situ hybridization

    Article • Leukemia, September 2001, Nature

    Dr ALESSANDRO Gozzetti, FRANCESC SOLE

  162. Fluorescence in situ hybridization: Uses and limitations

    Article • Seminars in Hematology, October 2000, Elsevier

    Dr ALESSANDRO Gozzetti

  163. Fluorescence in situ hybridization: Uses and limitations

    Article • Seminars in Hematology, October 2000, Elsevier

    Dr ALESSANDRO Gozzetti

  164. Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma

    Article • Journal of Clinical Oncology, June 2000, American Society of Clinical Oncology (ASCO)

    Dr ALESSANDRO Gozzetti

  165. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma

    Article • Bone Marrow Transplantation, June 1998, Nature

    Dr ALESSANDRO Gozzetti

  166. Selection and Transplantation of Autologous Hematopoietic CD34+Cells for Patients with Multiple Myeloma

    Article • Leukemia & Lymphoma, January 1997, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  167. Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports

    Article • Stem Cells, January 1996, Wiley

    Dr ALESSANDRO Gozzetti

  168. Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation (ABMT) for Lymphoma Patients

    Article • January 1996, Springer Science + Business Media

    Dr ALESSANDRO Gozzetti

  169. Combined Use of Growth Factors to Stimulate the Proliferation of Hematopoietic Progenitor Cells after Autologous Bone Marrow Transplantation for Lymphoma Patients

    Article • Acta Haematologica, January 1996, Karger Publishers

    Dr ALESSANDRO Gozzetti

  170. Adult Lymphoblastic Lymphoma: Clinical Features and Prognostic Factors in 53 Patients

    Article • Leukemia & Lymphoma, January 1996, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  171. Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma

    Article • Leukemia & Lymphoma, January 1996, Taylor & Francis

    Dr ALESSANDRO Gozzetti

  172. 6The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma

    Article • Baillière s Clinical Haematology, December 1995, Elsevier

    Dr ALESSANDRO Gozzetti

  173. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

    Article • Annals of Oncology, August 1993, Elsevier

    Dr ALESSANDRO Gozzetti